Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 140

1.

Transfusion-Related Acute Lung Injury (TRALI) in two Thalassaemia Patients Caused by the Same Multiparous Blood Donor.

Kolnagou A, Kontoghiorghe CN, Kontoghiorghes GJ.

Mediterr J Hematol Infect Dis. 2017 Oct 18;9(1):e2017060. doi: 10.4084/MJHID.2017.060. eCollection 2017.

2.

Chelation protocols for the elimination and prevention of iron overload in thalassaemia.

Kolnagou A, Kontoghiorghes GJ.

Front Biosci (Landmark Ed). 2018 Jan 1;23:1082-1098.

PMID:
28930590
3.

New targeted therapies and diagnostic methods for iron overload diseases.

Kolnagou A, Kontoghiorghe CN, Kontoghiorghes GJ.

Front Biosci (Schol Ed). 2018 Jan 1;10:1-20. Review.

PMID:
28930516
4.

The aim of iron chelation therapy in thalassaemia.

Kontoghiorghes GJ.

Eur J Haematol. 2017 Nov;99(5):465-466. doi: 10.1111/ejh.12939. Epub 2017 Sep 13. No abstract available.

PMID:
28833560
5.

Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.

Kolnagou A, Kontoghiorghe CN, Kontoghiorghes GJ.

Drug Res (Stuttg). 2017 Jul;67(7):404-411. doi: 10.1055/s-0043-102691. Epub 2017 Mar 20.

PMID:
28320041
6.

New developments and controversies in iron metabolism and iron chelation therapy.

Kontoghiorghe CN, Kontoghiorghes GJ.

World J Methodol. 2016 Mar 26;6(1):1-19. doi: 10.5662/wjm.v6.i1.1. eCollection 2016 Mar 26.

7.

Dietary and pharmacological factors affecting iron absorption in mice and man (Comment for a Letter to the editor).

Kontoghiorghe CN, Kolnagou A, Kontoghiorghes GJ.

Haematologica. 2016 Mar;101(3):e120-1. doi: 10.3324/haematol.2015.138255. No abstract available.

8.
9.

Phytochelators Intended for Clinical Use in Iron Overload, Other Diseases of Iron Imbalance and Free Radical Pathology.

Kontoghiorghe CN, Kolnagou A, Kontoghiorghes GJ.

Molecules. 2015 Nov 23;20(11):20841-72. doi: 10.3390/molecules201119725. Review.

10.

Characterization of the neuroprotective potential of derivatives of the iron chelating drug deferiprone.

Maher P, Kontoghiorghes GJ.

Neurochem Res. 2015 Mar;40(3):609-20. doi: 10.1007/s11064-014-1508-7. Epub 2015 Jan 6.

PMID:
25559767
11.

Transition of Thalassaemia and Friedreich ataxia from fatal to chronic diseases.

Kolnagou A, Kontoghiorghe CN, Kontoghiorghes GJ.

World J Methodol. 2014 Dec 26;4(4):197-218. doi: 10.5662/wjm.v4.i4.197. eCollection 2014 Dec 26. Review.

12.

Inhibition of Fe(2+)- and Fe(3+)- induced hydroxyl radical production by the iron-chelating drug deferiprone.

Timoshnikov VA, Kobzeva TV, Polyakov NE, Kontoghiorghes GJ.

Free Radic Biol Med. 2015 Jan;78:118-22. doi: 10.1016/j.freeradbiomed.2014.10.513. Epub 2014 Oct 29.

PMID:
25451643
13.

World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.

Kontoghiorghe CN, Andreou N, Constantinou K, Kontoghiorghes GJ.

World J Methodol. 2014 Sep 26;4(3):163-88. doi: 10.5662/wjm.v4.i3.163. eCollection 2014 Sep 26. Review.

14.

Antioxidant targeting by deferiprone in diseases related to oxidative damage.

Kontoghiorghe CN, Kolnagou A, Kontoghiorghes GJ.

Front Biosci (Landmark Ed). 2014 Jun 1;19:862-85. Review.

PMID:
24896322
16.
17.

Potential clinical applications of chelating drugs in diseases targeting transferrin-bound iron and other metals.

Kontoghiorghe CN, Kolnagou A, Kontoghiorghes GJ.

Expert Opin Investig Drugs. 2013 May;22(5):591-618. doi: 10.1517/13543784.2013.787408. Review.

PMID:
23586878
18.

Turning a blind eye to deferasirox's toxicity?

Kontoghiorghes GJ.

Lancet. 2013 Apr 6;381(9873):1183-4. doi: 10.1016/S0140-6736(13)60799-0. No abstract available.

PMID:
23561999
19.

The importance of spleen, spleen iron, and splenectomy for determining total body iron load, ferrikinetics, and iron toxicity in thalassemia major patients.

Kolnagou A, Michaelides Y, Kontoghiorghe CN, Kontoghiorghes GJ.

Toxicol Mech Methods. 2013 Jan;23(1):34-41. doi: 10.3109/15376516.2012.735278.

PMID:
23039902
20.

EDTA chelation reappraisal following new clinical trials and regular use in millions of patients: review of preliminary findings and risk/benefit assessment.

Born T, Kontoghiorghe CN, Spyrou A, Kolnagou A, Kontoghiorghes GJ.

Toxicol Mech Methods. 2013 Jan;23(1):11-7. doi: 10.3109/15376516.2012.730562. Epub 2012 Oct 19.

PMID:
22991933

Supplemental Content

Loading ...
Support Center